New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:57 EDTRLYPRelypsa price target raised to $41 from $25 at Stifel
Stifel believes that recent data emphasizes the primary role of Relypsa's patiromer in treating patients following the initial abatement of hyperkalemia, and it expects doctors to be impressed by the data. Stifel now expects Relypsa to launch a partnership in Europe and collect 45% royalties there starting in FY17. It keeps a Buy rating on the shares.
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
15:31 EDTRLYP5AM Ventures III lowers stake in Relypsa to 5.89% from 9.38%
Subscribe for More Information
March 26, 2015
19:04 EDTRLYPRelypsa Phase 3 data says Patiromer FOS prevents recurrence of hyperkalemia
Relypsa announced that data from a Phase 3 clinical program showing that Patiromer for Oral Suspension, or Patiromer FOS, the company's lead product candidate, was effective in reducing potassium levels and preventing a recurrence of hyperkalemia in patients with advanced chronic kidney disease receiving ongoing treatment with renin-angiotensin-aldosterone system inhibitors were presented as a poster at the National Kidney Foundation 2015 Spring Clinical Meeting. The results are from a sub-group analysis of the two part Phase 3 trial, OPAL-HK, conducted under a Special Protocol Assessment with the FDA that was led by Matthew Weir, M.D., Professor and Director, Division of Nephrology, University of Maryland School of Medicine. The Phase 3 OPAL-HK trial primary outcomes, previously published in the New England Journal of Medicine, were combined with results from Relypsa's broader clinical development program to support the company's New Drug Application, or NDA, for Patiromer FOS. The FDA has assigned a Prescription Drug User Fee Act, or PDUFA, action date of October 21 for completion of the review of the NDA.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use